Literature DB >> 20157288

Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters.

M Poggi1, C Pascucci, S Monti, P Pugliese, C Lauri, G Amodeo, G Girelli, V Toscano.   

Abstract

BACKGROUND: Dysfunction of GH-IGF-I axis has been described in many patients affected by β-thalassemia major (TM), especially in children and in adolescents. Recent studies have demonstrated the necessity to evaluate adult patients affected by TM to establish the presence of this alteration which could be relevant in the pathogenesis of cardiac and bone disease, frequently present in this hematological condition. The pathogenesis of this alteration, correlated in the past with iron overload, is not yet completely understood. AIM: The aim of this paper is to evaluate GH-IGF-I axis in a group of adult polytransfused β-thalassemic patients (TM) and to correlate the results with transfusional and chelation parameters. SUBJECTS AND METHODS: We performed an arginine plus GHRH stimulation test in 28 adult TM patients. Ferritin, IGF-I, liver enzymes, and liver iron concentration, assessed by a superconducting quantum interference device (SQUID) susceptometer were also determined. Moreover, in each patient we evaluated the bone status by a dual-energy X-ray absorptiometry study.
RESULTS: We found the presence of GH deficit in 9 patients (32.1%). There were no significant differences between the two groups regarding the value of ferritin, liver enzymes, and liver iron concentration, assessed by SQUID. The group affected by GH deficit showed a worse bone profile.
CONCLUSIONS: This study confirms the necessity to screen the status of GH/IGF-I axis in this group of patients, even in adult age. The presence of GH deficiency does not seem to be correlated with the efficacy parameters of transfusional and chelation therapy. Other mechanisms, additional to iron overload, could therefore play a role in the pathogenesis of this clinical condition. The presence of GH deficit seems to be very important on clinical aspects, like bone disease, that are crucial for quality of life in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157288     DOI: 10.1007/BF03346643

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

Review 1.  Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis.

Authors:  Peter Davidson; Ruairidh Milne; Deborah Chase; Cyrus Cooper
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

Review 2.  GH deficiency in the adult and bone.

Authors:  M Doga; S Bonadonna; M Gola; G Mazziotti; M Nuzzo; A Giustina
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

3.  Adult height in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies.

Authors:  Mohamad Maghnie; Linda Ambrosini; Marco Cappa; Gabriella Pozzobon; Lucia Ghizzoni; Maria Grazia Ubertini; Natascia di Iorgi; Carmine Tinelli; Sabrina Pilia; Giuseppe Chiumello; Renata Lorini; Sandro Loche
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

Review 4.  Clinical aspects of growth hormone deficiency in adults.

Authors:  H de Boer; G J Blok; E A Van der Veen
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

Review 5.  Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Authors:  Roland Fischer; Antonio Piga; Paul Harmatz; Peter Nielsen
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

6.  Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion.

Authors:  C Roth; A Pekrun; M Bartz; H Jarry; S Eber; M Lakomek; W Schröter
Journal:  Eur J Pediatr       Date:  1997-10       Impact factor: 3.183

Review 7.  Growth, puberty and endocrine function in beta-thalassaemia major.

Authors:  L C Low
Journal:  J Pediatr Endocrinol Metab       Date:  1997 Mar-Apr       Impact factor: 1.634

8.  Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites.

Authors:  Massimo Scacchi; Leila Danesi; Agnese Cattaneo; Elena Valassi; Francesca Pecori Giraldi; Crocetta Argento; Emanuela D'Angelo; Nadia Mirra; Vittorio Carnelli; Laura Zanaboni; Benedetta Tampieri; Maria Domenica Cappellini; Francesco Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-21       Impact factor: 3.478

9.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

10.  Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.

Authors: 
Journal:  Clin Endocrinol (Oxf)       Date:  1995-06       Impact factor: 3.478

View more
  8 in total

1.  Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis.

Authors:  C Pascucci; R V De Biase; D Savi; S Quattrucci; A M Isidori; C Lubrano; L Gnessi; A Lenzi
Journal:  J Endocrinol Invest       Date:  2017-11-02       Impact factor: 4.256

2.  Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.

Authors:  C Pascucci; R V De Biase; D Savi; S Quattrucci; L Gnessi; C Lubrano; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-04-20       Impact factor: 4.256

3.  The Correlation Between Iron Overload and Endocrine Function in Adult Transfusion-Dependent Beta-Thalassemia Patients with Growth Retardation.

Authors:  Tubagus Djumhana Atmakusuma; Faizal Drissa Hasibuan; Dyah Purnamasari
Journal:  J Blood Med       Date:  2021-08-17

4.  Insulin-like Growth Factor-1 (IGF-1): Demographic, Clinical and Laboratory Data in 120 Consecutive Adult Patients with Thalassaemia Major.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Giancarlo Candini; Mohamed Yassin; Giuseppe Raiola; Maria Concetta Galati; Rania Elalaily; Heba Elsedfy; Nicos Skordis; Piernicola Garofalo; Salvatore Anastasi; Saveria Campisi; Mehran Karimi; Christos Kattamis; Duran Canatan; Yurdanur Kilinc; Praveen Sobti; Bernadette Fiscina; Mohamed El Kholy
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

5.  Clinical and Biochemical Data of Adult Thalassemia Major patients (TM) with Multiple Endocrine Complications (MEC) versus TM Patients with Normal Endocrine Functions: A long-term Retrospective Study (40 years) in a Tertiary Care Center in Italy.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Christos Kattamis; Nada A Soliman; Rania Elalaily
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-12       Impact factor: 2.576

Review 6.  A contemporary therapeutic approach to bone disease in beta-thalassemia - a review.

Authors:  Dimitrios Stefanopoulos; Nikolaos A Papaioannou; Athanassios G Papavassiliou; George Mastorakos; Andromachi Vryonidou; Aikaterini Michou; Ismene A Dontas; George Lyritis; Eva Kassi; Symeon Tournis
Journal:  J Frailty Sarcopenia Falls       Date:  2018-03-01

7.  Growth hormone - insulin-like growth factor-I axis and bone mineral density in adults with thalassemia major.

Authors:  Ashraf Soliman; Vincenzo De Sanctis; Mohamed Yassin; Mohamed O Abdelrahman
Journal:  Indian J Endocrinol Metab       Date:  2014-01

8.  New Insights and Methods in the Approach to Thalassemia Major: The Lesson From the Case of Adrenal Insufficiency.

Authors:  Maurizio Poggi; Irene Samperi; Lorenza Mattia; Arianna Di Rocco; Cristina Iorio; Salvatore Monti; Giuseppe Pugliese; Vincenzo Toscano
Journal:  Front Mol Biosci       Date:  2020-01-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.